🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

There are many perverse incentives in US healthcare. Our duty as physicians is always to do the right thing for the patient in front of us regardless, even as we work to improve the incentive system. This is the essence of medical professionalism. It is the most important thing

I find learners often get confused about superiority vs non-inferiority testing. Here's 3 slides I made to (hopefully) demystify it:

Important data on the clinical landscape of amyloidosis in 🇮🇳! Congrats Sumeet Mirgh MD, DM and team!

Bispecific Antibodies (BsAbs) Reign in Blood Cancers: Top Studies from the ASCO 2025. Never miss an #ASCO25 update with us: t.ly/7TCD6 #LARVOL #BsAbs #Hematology #BloodCancer #CancerResearch #Oncology #OncologyInsights #CancerData #ClinicalTrials | Graham Collins |

New🚨 EMERGENCY PODCAST 🚨 episode Blood Cancer Talks! Following recent FDA ODAC proceedings, we dissect two pivotal trials & insights from FDA/panelists: 🔸 AQUILA: Daratumumab in high-risk SMM 🔸 STARGLO: Glofitamab in R/R DLBCL share.transistor.fm/s/bb61526b A short clip on STARGLO:

My immigrant dad asked me where the missing 10% went when I scored a 90. He came to America for the chance to work hard & pursue excellence. Giving A’s for 80% & no homework is not equity—it betrays the American Dream and every parent who wants more for their kids.

Shamelessly stealing the concept of emergency podcasts from The Rest Is Politics but don’t worry we aren’t talking politics - we talk AQUILA, STARGLO, FDA ODAC Come into the weeds of clinical trials with us Glofitamab-GemOx for R/R DLBCL #starglo #lymsm #ODAC Common Sense Oncology OncoAlert

Excited to share our latest paper calling for a modernized approach to AE measurement, analysis, visualization, & reporting led by Ajay Major, MD, MBA! 📊🧬#hematology #ClinicalTrials #lymsm #dataviz authors.elsevier.com/c/1lAZ98MsWYNW…

Free copy of our commentary in Nature Reviews on myeloma clinical trials and how we can answer better questions that matter to patients (not pharma) NRCO Mohyuddin Goodman.pdf - Google Drivem drive.google.com/file/d/1kk22Fl…

Amazing table on post-induction MRD-negative rate in the pivotal RCTs thus far! I wish we had a CD38-VRD vs CD38-KRD RCT in fit/transplant-eligible patients, but unlikely that it will ever happen! #ASCO25 #mmsm

Aaron Goodman - “Papa Heme” This👆🏽! Also, if a standard of care is approved for later line, only a small proportion getting it off a clinical trial is also a point of concern. Clearly these were trial eligible candidates. I can understand some do decline and not equal for all diseases/cancers. #ASCO25

Cancer trials with a federal lead sponsor compared to industry sponsor are more likely to investigate de-escalation interventions, rare cancers, and children, among other things using data from clinicaltrials.gov from 2008-2022. #ASCO25 poster by Joe Unger at Fred Hutch Cancer Center.

What if this was a drug ?🙂 🆕 NEJM | June 2025 🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer 📦 RCT | n=889 | Median FU: 7.9 yrs 🟠 3-yr structured aerobic program vs health ed alone 📈 Primary Endpoint: Disease-Free Survival (DFS) 🔹 HR 0.72

These are such great points re: CHALLENGE & I agree w most, but: 1) I actually do think the effect size is believable...the absolute gain from a lot of the cancer drugs isn't that much. And of course when you put it as a %, the difference seems much more impressive than absolute

#mmsm #ASCO25 Rapid Oral myeloma sessions Raj Chakraborty LINKER-MM2 with linvo and carfilzomib Small no of pts ORR are high with short follow up Thrombocytopenia G3 or higher quite high at 40% as well as G3 or higher in 44%

#mmsm #ASCO25 Oral myeloma session CARTITUDE-1 long term follow up The nice tail in the curve with one out of three patients being disease free, off therapy and alive (great results) - those are the ones with deep responses

Cartitude-1 LTFU data is very exciting. Unprecedented results! But I think we need to be extremely cautious calling this a cure or functional cure. For me, cure in MM is when I can look a patient in their eyes and tell them they don't need to return to clinic. Not there yet.

Impressive efficacy data from NEXICART-2 in AL #Amyloidosis at #ASCO25! Few thoughts: 1. With low plasma cell burden in relapsed/refractory AL, I do expect ~90-100% MRD-negative heme-CR rate with BCMA CAR T (The 3 VGPR/low-dFLC PRs will deepen into heme-CR with a bit more

Most viewed this week from JAMA Oncology: While phase 3 oncology trials frequently report success based on alternative endpoints, actual enhancements in overall survival and quality of life are uncommon. ja.ma/4jyRiED